Scalper1 News
Allergan (AGN), the specialty-drug giant formerly known as Actavis, said Wednesday that it’s acquiring biotech Kythera (KYTH) for $2.1 billion in cash and stock, sending both stocks up in early trading. Just seven weeks ago, Kythera won FDA approval of its first product, Kybella, an injection for “submental fullness,” i.e. double chin. The original Allergan, which Actavis acquired in March before changing its name on Monday, was best known for its Scalper1 News
Scalper1 News